Cargando…
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
AIMS: Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with optimal therapy. We assessed the treatment res...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120366/ https://www.ncbi.nlm.nih.gov/pubmed/33682334 http://dx.doi.org/10.1002/ehf2.13285 |